Literature DB >> 1355428

Interaction of talinolol and sulfasalazine in the human gastrointestinal tract.

B Terhaag1, U Palm, H Sahre, K Richter, R Oertel.   

Abstract

The absorption of talinolol (TA) 50 mg was investigated without and together with the co-administration of sulfasalazine (SASP) 4 g in 11 healthy young volunteers, in order to clarify gastrointestinal transit of TA. Without SASP, the tmax of TA was 2.8 h, Cmax was 112 ng.ml-1 and the half life was 12 h; the AUCo-t was 958 ng.ml-1.h. In the case of concomitant administration of SASP, TA was found only in serum from 3 individuals, with a Cmax of 23 ng.ml-1 and a mean AUCo-t of 84 ng.ml-1.h. TA was not detectable in 5 subjects and it was at the limit of detection (2 ng.ml-1) in 3 subjects. Pharmacokinetic analysis was not possible in any of those individuals. The reason for the interaction appears to be the adsorption of TA by SASP. An interval of 2-3 h should elapse between giving SASP and other drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355428     DOI: 10.1007/bf00280137

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data.

Authors:  R C Shumaker
Journal:  Drug Metab Rev       Date:  1986       Impact factor: 4.518

2.  [Determination of talinolol in human plasma by high-performance liquid chromatography (author's transl)].

Authors:  H Pötter; M Hülm; K Richter
Journal:  J Chromatogr       Date:  1982-05-28

3.  [The pH-dependent lipid solubility of drug groups].

Authors:  G le Petit
Journal:  Pharmazie       Date:  1985-11       Impact factor: 1.267

4.  A pharmacological method of measuring mouth caecal transit time in man.

Authors:  M Kennedy; P Chinwah; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

5.  Effect of sulfasalazine on digoxin bioavailability.

Authors:  R P Juhl; R W Summers; J K Guillory; S M Blaug; F H Cheng; D D Brown
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

6.  The biliary elimination of the selective beta-receptor blocking drug talinolol in man.

Authors:  B Terhaag; T Gramatté; K Richter; J Voss; K Feller
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-04

7.  [Modification of orocecal transit time of salazosulfapyridine by atropine and metoclopramide in healthy probands].

Authors:  B Terhaag; A Neugebauer
Journal:  Dtsch Z Verdau Stoffwechselkr       Date:  1986

8.  Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine).

Authors:  J L Franklin; H H Rosenberg
Journal:  Gastroenterology       Date:  1973-04       Impact factor: 22.682

  8 in total
  3 in total

1.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

2.  Evaluation of Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) for Poorly Water-Soluble Talinolol: Preparation, in vitro and in vivo Assessment.

Authors:  Mohsin Kazi; Mohammed Al-Swairi; Ajaz Ahmad; Mohammad Raish; Fars K Alanazi; Mohamed M Badran; Azmat Ali Khan; Amer M Alanazi; Muhammad Delwar Hussain
Journal:  Front Pharmacol       Date:  2019-05-02       Impact factor: 5.810

3.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.